CAMBRIDGE, Mass. — November 24, 2025 — Leads & Copy — Seres Therapeutics, Inc. (Nasdaq: MCRB), a live biotherapeutics company, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m. ET.
A live webcast of the chat will be accessible through the “Events and Presentations” tab in the “Investors and News” section of Seres Therapeutics’ website. The webcast will be available for replay following the event.
Seres Therapeutics, a clinical-stage company, focuses on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024.
The company is developing SER-155, a therapeutic that has received Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allo-HSCT. SER-155 also has Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT.
SER-155 demonstrated a significant reduction in bloodstream infections and related complications, compared to a placebo, in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the company’s other pipeline programs target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation. This is different from the donor-sourced production process used for VOWST™.
Besides allo-HSCT, Seres intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations. These populations include autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, intensive care unit patients, and long-term acute care facilities patients.
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
Source: Seres Therapeutics
